Y Intercept Hong Kong Ltd Has $2.25 Million Holdings in Travere Therapeutics, Inc. $TVTX

Y Intercept Hong Kong Ltd increased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 38.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 94,325 shares of the company’s stock after acquiring an additional 26,325 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.11% of Travere Therapeutics worth $2,254,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TVTX. Emerald Mutual Fund Advisers Trust grew its position in shares of Travere Therapeutics by 5.2% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,200,942 shares of the company’s stock valued at $28,703,000 after purchasing an additional 59,514 shares during the last quarter. Emerald Advisers LLC lifted its position in shares of Travere Therapeutics by 2.6% during the 3rd quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock worth $51,308,000 after purchasing an additional 55,407 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Travere Therapeutics by 67.7% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 213,918 shares of the company’s stock valued at $5,113,000 after purchasing an additional 86,336 shares during the period. Oak Ridge Investments LLC grew its holdings in Travere Therapeutics by 32.5% in the 3rd quarter. Oak Ridge Investments LLC now owns 68,232 shares of the company’s stock valued at $1,631,000 after buying an additional 16,755 shares during the last quarter. Finally, Stephens Investment Management Group LLC bought a new position in Travere Therapeutics in the 3rd quarter worth approximately $38,232,000.

Insiders Place Their Bets

In related news, CAO Sandra Calvin sold 7,402 shares of the stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $40.00, for a total value of $296,080.00. Following the completion of the transaction, the chief accounting officer owned 38,233 shares of the company’s stock, valued at $1,529,320. This represents a 16.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Peter Heerma sold 4,980 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $40.00, for a total value of $199,200.00. Following the sale, the insider directly owned 113,013 shares in the company, valued at $4,520,520. The trade was a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 270,564 shares of company stock valued at $9,650,917 over the last 90 days. Company insiders own 4.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research report on Friday, November 28th. Piper Sandler boosted their target price on shares of Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Guggenheim restated a “buy” rating and issued a $49.00 price target on shares of Travere Therapeutics in a research report on Wednesday, January 14th. Finally, TD Cowen restated a “buy” rating on shares of Travere Therapeutics in a report on Friday, October 31st. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $38.86.

Travere Therapeutics Stock Up 0.8%

TVTX opened at $30.28 on Thursday. The company has a market capitalization of $2.71 billion, a P/E ratio of -28.57, a P/E/G ratio of 0.99 and a beta of 0.85. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. The firm’s fifty day moving average price is $34.35 and its two-hundred day moving average price is $27.24. Travere Therapeutics, Inc. has a fifty-two week low of $12.91 and a fifty-two week high of $42.13.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The company had revenue of $164.86 million during the quarter, compared to analysts’ expectations of $106.09 million. During the same quarter in the prior year, the company posted ($0.70) EPS. The business’s revenue was up 162.1% on a year-over-year basis. On average, analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Travere Therapeutics Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.